Interpace Biosciences (OTCMKTS:IDXG) Announces Earnings Results

Interpace Biosciences (OTCMKTS:IDXG) issued its earnings results on Monday. The business services provider reported $0.01 EPS for the quarter, Zacks reports. Interpace Biosciences had a net margin of 65.25% and a return on equity of 219.07%.

Interpace Biosciences Price Performance

OTCMKTS:IDXG opened at $1.70 on Tuesday. The business’s 50-day simple moving average is $1.61 and its 200-day simple moving average is $1.77. Interpace Biosciences has a fifty-two week low of $0.77 and a fifty-two week high of $2.40. The stock has a market capitalization of $7.53 million, a PE ratio of -34.00 and a beta of 0.61.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.